link
Bookmarks
Ultrasound Contrast Agents: Lumason/SonoVue
John Eisenbrey, PhD; Christian Greis, PhD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe

KEY FACTS

  • Terminology

    • Clinical Implications

      • Imaging Recommendations

        TERMINOLOGY

        • Definitions

          • Lumason (as marketed in United States) or SonoVue (as marketed worldwide)
            • US contrast agent manufactured by Bracco Suisse SA, Geneva, Switzerland

        CLINICAL IMPLICATIONS

        • Contrast Agent

          • Pharmacokinetics

            • Storage and Handling

              DOSAGE AND ADMINISTRATION

              • Preparation Instructions

                • Injection Instructions

                  • Manufacturer-Recommended Dosages

                    • Dosage Variations

                      • Technical Pitfalls and Challenges

                        CONTRAINDICATIONS

                        • Use of Lumason/SonoVue

                          PRECAUTIONS

                          • Adverse Reactions

                            • Cardiopulmonary Reactions

                              • Hypersensitivity Reactions

                                • Systemic Embolization

                                  USE IN SPECIFIC POPULATIONS

                                  • Pregnancy

                                    • Lactation

                                      Selected References

                                      1. Seitz K et al: A milestone: Approval of CEUS for diagnostic liver imaging in adults and children in the USA. Ultraschall Med. 37(3):229-32, 2016
                                      2. Piscaglia F et al: The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 32(9):1369-75, 2006
                                      3. Morel DR et al: Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol. 35(1):80-5, 2000
                                      4. Schneider M: Characteristics of SonoVuetrade mark. Echocardiography. 16(7, Pt 2):743-746, 1999
                                      5. Schneider M: SonoVue, a new ultrasound contrast agent. Eur Radiol. 9 Suppl 3:S347-8, 1999
                                      6. Lumason Product Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203684s002lbl.pdf. Accessed November 2018.
                                      7. SonoVue Product Insert. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000303/WC500055380.pdf. Accessed November 2018.
                                      Related Anatomy
                                      Loading...
                                      Related Differential Diagnoses
                                      Loading...
                                      References
                                      Tables

                                      Tables

                                      KEY FACTS

                                      • Terminology

                                        • Clinical Implications

                                          • Imaging Recommendations

                                            TERMINOLOGY

                                            • Definitions

                                              • Lumason (as marketed in United States) or SonoVue (as marketed worldwide)
                                                • US contrast agent manufactured by Bracco Suisse SA, Geneva, Switzerland

                                            CLINICAL IMPLICATIONS

                                            • Contrast Agent

                                              • Pharmacokinetics

                                                • Storage and Handling

                                                  DOSAGE AND ADMINISTRATION

                                                  • Preparation Instructions

                                                    • Injection Instructions

                                                      • Manufacturer-Recommended Dosages

                                                        • Dosage Variations

                                                          • Technical Pitfalls and Challenges

                                                            CONTRAINDICATIONS

                                                            • Use of Lumason/SonoVue

                                                              PRECAUTIONS

                                                              • Adverse Reactions

                                                                • Cardiopulmonary Reactions

                                                                  • Hypersensitivity Reactions

                                                                    • Systemic Embolization

                                                                      USE IN SPECIFIC POPULATIONS

                                                                      • Pregnancy

                                                                        • Lactation

                                                                          Selected References

                                                                          1. Seitz K et al: A milestone: Approval of CEUS for diagnostic liver imaging in adults and children in the USA. Ultraschall Med. 37(3):229-32, 2016
                                                                          2. Piscaglia F et al: The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 32(9):1369-75, 2006
                                                                          3. Morel DR et al: Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol. 35(1):80-5, 2000
                                                                          4. Schneider M: Characteristics of SonoVuetrade mark. Echocardiography. 16(7, Pt 2):743-746, 1999
                                                                          5. Schneider M: SonoVue, a new ultrasound contrast agent. Eur Radiol. 9 Suppl 3:S347-8, 1999
                                                                          6. Lumason Product Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203684s002lbl.pdf. Accessed November 2018.
                                                                          7. SonoVue Product Insert. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000303/WC500055380.pdf. Accessed November 2018.